Prof Markus Müschen talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about how inhibitory phosphatases regulate the survival of B-lymphocytes.
He explains how phosphatases are necessary for oncogene signalling and the inhibition of these may prevent relapse and overcome drug resistance in acute lymphoblastic leukaemia (ALL).
Prof Müschen mentions the possibility of incorporating precision medicine in this approach, along with the differences between various subtypes of leukaemia.
He concludes by summarising the specific therapeutic targets in this signalling pathway.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.